8-K current report · filed Nov 16, 2026

Aquestive Therapeutics, Inc. (AQST) 8-K Current Report: November 16, 2026

Item 7.01Item EX-99.1AQST overview

Short answer

Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor presentation disclosed at the Jefferies Global Healthcare Conference on November 16, 2026.

Aquestive Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Investor presentation disclosed at the Jefferies Global Healthcare Conference on November 16, 2026
  • Presentation provides management’s latest investor messaging and may influence analyst expectations
  • Exhibit 99.1 contains the substantive presentation materials for review

Item EX-99.1 · Exhibit EX-99.1

  • Anaphylm NDA resubmission accepted, with FDA PDUFA goal date March 16, 2027, creating a major near-term regulatory catalyst
  • Cash and equivalents $90.3 million at September 30, 2026, with potential access to $75 million RTW funding and $20 million Oaktree debt
  • Planned U.S. launch contingent on approval, targeting approximately 75 sales representatives and approximately 8,000 priority healthcare providers
  • Canada filing targeted by year-end 2026 and European Union filing in Q1 2027, with ex-U.S. licensing rights available
  • Pipeline opportunity exceeds $1.5 billion in potential peak annual net sales, including Anaphylm, Libervant and AQST-108 estimates

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aquestive Therapeutics, Inc. 8-K filings

Get the next AQST 8-K as it lands

Follow AQST for push alerts, or ask the research agent what this filing means.